Log In
BCIQ
Print this Print this
 

Varubi, oral rolapitant (SCH 619734)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionNeurokinin 1 (NK1) substance P receptor (TACR1) antagonist
Molecular Target Neurokinin 1 (NK1) substance P receptor (TACR1)
Mechanism of ActionNeurokinin-1 (NK-1) (Substance P) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent chemotherapy-induced nausea and vomiting (CINV); Treat post-operative nausea and vomiting (PONV)
Regulatory Designation
PartnerJiangsu Hengrui Medicine Co. Ltd.;
Tesaro Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

0

$6.0M

$115.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today